DOCSLIB.ORG

Toxicology Manager Document Type: LC & LC/MS/M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxicology Manager Document Type: LC & LC/MS/M Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 1.0 Purpose 1.1 This assay is used to qualitatively identify certain synthetic cathinones, amphetamine-like compounds, known as “Bath Salts” by LC-MS/MS. 2.0 Scope 2.1 The method is intended for finding evidence of “Bath Salt” compounds in blood and urine specimens, as well as other fluids and tissues. The method specifically scans for mephedrone, methedrone, methylone, butylone, ethylone, methylene- dioxypyrovalerone (MDPV), naphyrone, alpha-pyrrolidinopropiophenone (α- PPP), alpha-pyrrolidinopentiophenone (α-PVP), pentedrone, and 4'-Methyl-α- pyrrolidinopropiophenone (Methylpyrrolidinopropiophenone,4-MePPP, M-PPP). Other bath salt compounds and 2-propanal variants are possible, but not detected by this method. 3.0 Definitions and Abbreviations 3.1 No method-specific or non-standard terms are used in this procedure. 4.0 Materials 4.1 Instruments and Equipment 4.1.1 Pipettes and tips 4.1.2 13 x 100 mm screw cap test tubes and caps 4.1.3 16 x 100 mm test tubes 4.1.4 Vortex mixer 4.1.5 Centrifuge 4.1.6 Nitrogen stream evaporator and compressed nitrogen gas 4.1.7 Autosampler vials and septum caps 4.1.8 Filter and disposable syringes 4.1.9 Agilent LCMSMS 4.2 Reagents 4.2.1 Acetonitrile: HPLC Grade. 4.2.2 Water: HPLC Grade. 4.2.3 Ethyl Acetate: HPLC Grade Page 1 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 4.2.4 Methanol: HPLC Grade 4.2.5 pH 12 Saturated Sodium Borate Buffer A. Weigh 100 g of Sodium Tetraborate B. Add to 900 mL of deionized water. C. Heat with stirring bar in a 1 L beaker until dissolved. D. Add 50 mL of 10 N Sodium Hydroxide while stirring, allow to cool. E. Adjust to pH 12 + 0.2 with 10 N NaOH. F. Stable 6 months at room temperature. 4.2.6 Mobile phase A A. Measure 1 L of deionized water into a clean 1000 ml Media bottle. B. Add 0.45g of ammonium formate to the 1 L of Millipore Milli Q or HPLC grade water. C. Mix well. D. Stable for 3 months at room temperature. E. Label as 7 mM Ammonium formate in H2O (Mobile Phase A). Include preparation and expiration date (3months) and initials of preparer. F. Stable at room temperature. 4.2.7 Mobile phase B: Acetonitrile. A. Stable for 3 months at room temperature. 4.2.8 Reconstitution buffer (90:10 7mM Ammonium Formate in H2O:ACN) A. Add 5 mL of acetonitrile to 50 mL conical vial. B. Add 45 mL of 7mM ammonium formate (mobile phase buffer A used in benzodiazepine methods). C. Cap and mix by inversion or vortexing. D. Stable for 3 months at room temperature. 4.3 Stock Standards Note: Certified Reference Materials should be used within manufacturer’s expiration date and be stored at the recommended storage temperature. 4.3.1 Butylone-D3 HCl, 100 µg/mL from Cerilliant #B-046 or equivalent 4.3.2 Butylone HCl, 1.0 mg/mL from Cerilliant #B-045 or equivalent 4.3.3 Ethylone HCl, 1.0 mg/mL from Cerilliant #E-071 or equivalent 4.3.4 Mephedrone HCl, 1.0 mg/mL from Cerilliant #M-138 or equivalent 4.3.5 Methylone HCl, 1.0 mg/mL from Cerilliant #M-140 or equivalent 4.3.6 MDPV HCl, 1.0 mg/mL from Cerilliant #M-146 or equivalent Page 2 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 4.3.7 Methedrone HCl, 1.0 mg/mL from Cerilliant #M-147 or equivalent 4.3.8 Naphyrone HCl, 1.0 mg/mL from Cerilliant #N-067 or equivalent 4.3.9 Pentedrone HCl, 1.0 mg/mL from Cerilliant #P-087 or equivalent 4.3.10 α-PPP 1.0 mg/mL from Cayman # 10445 or equivalent 4.3.11 α-PVP 1.0 mg/mL from Cayman # 9001083 or equivalent 4.3.12 M-PPP 1.0 mg/mL from Cayman # 10446 or equivalent 4.4 Working Standards / Controls Note: Prepared working standards/QCs may not have an expiration date that exceeds the expiration date of the stock standard used to prepare it. Note: Prepared working internal standards/standards/controls are stable until the manufacturer’s expiration date when stored at manufacturer’s recommended storage temperature. 4.4.1 Bath Salts Control (A) 5 µg/mL A. Pipette 25 µL of the following stocks into a 5 mL volumetric flask: a. Mephedrone b. Methedrone c. Methylone d. Butylone e. Ethylone f. MDPV g. Naphyrone B. QS to 5 mL with Methanol. C. Label as Bath Salts Control (A). Include name of preparer, date prepared, expiration date, and concentration. 4.4.2 Bath Salts Control (B) 5 µg/mL A. Pipette 25 µL of the following stocks into a 5 mL volumetric flask: a. Pentedrone b. α-PPP c. α-PVP d. M-PPP B. QS to 5 mL with Methanol. C. Label as Bath Salts Control (B). Include name of preparer, date prepared, expiration date, and concentration. 4.4.3 Bath Salts Control (C) 0.5 µg/mL A. Pipette 2.5 mL of Control A and 2.5 mL of Control B into a 25 mL Page 3 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 volumetric flask B. QS to 25 mL with Methanol C. Label as Bath Salts Control (C). Include name of preparer, date prepared, expiration date, and concentration. 4.4.4 Bath Salts Internal Standard 1 µg/mL A. Pipette 100 µL of the stock 100 µg/mL Butylone-D3 into a 10 mL volumetric flask. B. QS to 10 mL with methanol. C. Using a white color label, mark as Bath Salts Internal Standard. Include name of preparer, date prepared, expiration date, and concentration. 5.0 Procedure 5.1 Standards and Controls 5.1.1 Label a sufficient number of 13 x 100 mm screw cap tubes. 5.1.2 Add the indicated volumes (µL) of Working Controls. Tube contents Target QC C I.S. (ng/mL) (0.5 µg/mL) (1 µg/mL) Reagent Blank --- --- --- Negative QC --- --- 5 QC 1 100 100 5 QC 2 5 5 5 5.1.3 Add 5 μL of the Working Internal Standard solution to all tubes except the reagent blank. 5.2 Sample Preparation and Extraction 5.2.1 Using labeled 13 X 100 mm screw cap tubes, pipet 0.5 mL of negative blood into standard/QC tubes and 0.5 mL specimen into case tubes. 5.2.2 Add 0.2 mL pH 12 saturated sodium borate and vortex for 5 seconds. 5.2.3 Add 2 mL of ethyl acetate and vortex for 5 seconds. Page 4 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 5.2.4 Centrifuge at 3500 RPM for 5 minutes. 5.2.5 Transfer organic layer into a fresh 16 x 100 mm tube. 5.2.6 Evaporate solvent under nitrogen gas stream. 5.2.7 Reconstitute in 1.0 mL reconstitution buffer (90% of 7mM Ammonium Formate in H2O and 10% of Acetonitrile). 5.2.8 Filter specimen with filters attached to disposable syringes 5.2.9 Transfer filtrate to autosampler vials 5.2.10 Analyze samples by LCMSMS 5.3 Instrument Parameters 5.3.1 Table 2: Mobile Phase A 7mM Ammonium Formate in Water B Acetonitrile 5.3.2 Table 3: LC Conditions Internal Particle Column Length Column Flow Diameter Size C18 100 mm 3 mm 3.5µm 0.25 mL/min HPLC Program (Gradient) Time (min.) %A %B 0 80 20 3 80 20 4 5 95 7.49 5 95 7.5 80 20 14 80 20 5.3.3 Table 4: QQQ Conditions Collision Precursor Product Ions Compound Energy Ion (Quant/Qual) (V) Naphyrone 282.2 126 25 Page 5 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 155 25 126 25 MDPV 276.1 135 25 174 15 Ethylone 222.2 204 10 174 15 Butylone 222.1 204 10 160 15 Methylone 208.1 132 30 176 5 Methedrone 194.1 161 20 160 10 Mephedrone 178.1 144 35 177 15 Butylone-D3 225.1 207 10 174 8 Pentedrone 192.2 91.1 20 105.1 24 α-PPP 204.1 98.1 24 91.1 24 α-PVP 232.2 77.1 55 119.1 24 M-PPP 218.2 147.1 16 5.3.4 Start sequence with a blank mobile phase injection using the pre-run method to equilibrate the column for bath salts method. A. Table 5: LC Condition (Bath Salts Pre-run.m) HPLC Program (Gradient) Time (min.) Flow (mL/min) %A %B 0 0.3 80 20 2 0.3 5 95 5 0.3 5 95 6 0.3 80 20 16 0.3 80 20 17 0.3 5 95 20 0.3 5 95 21 0.3 80 20 30 0.3 80 20 Page 6 of 8 Harris County Institute of Forensic Sciences Approved by: Toxicology Section: Toxicology Manager Document Type: LC & LC/MS/MS Procedure No.: TOX.LC.3496 Title: Bath Salts Confirmation by LCMSMS Rev.: 7 5.4 Table 5: Sample Injection Sequence Position Sample Number 1 MPB – Pre-Run Method 2 Reagent Blank 3 Negative control 4 Control 1 3 Negative control (reinjection) 5 Continue with samples Run the extracted (5ng/mL) positive control at the end of the run.
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Treatment, Prevention and Harm Reduction Interventions for Different Forms of ATS Use
    Correlation European Harm Reduction C Network Briefing Paper Treatment, prevention and harm reduction interventions for different forms of ATS use Correlation European Harm Reduction C Network 1 Correlation European Harm Reduction C Network Colophon This C-EHRN Briefing Paper was developed by Rafalea Rigoni, Nienke Liebregts and Katrin Schiffer and is based on the results and findings of the ATTUNE study and other relevant literature. More info via: wwww.correlation-net.org https://www.correlation-net.org/attune/ Authors: Rafaela Rigoni Nienke Liebregts Katrin Schiffer Review: Graham Shaw Copyright ©2021 Coyright remains with the publisher. Publisher: De Regenboog Groep/ Correlation-European Harm Reduction Network Stadhouderskade 159 1074BC Amsterdam Netherlands Correlation European Harm Reduction C Network Correlation-European Harm Reduction Network is co-funded by the European Commission This project has been made possible by 2 Correlation European Harm Reduction C Network List of Acronyms 4-FA 4-Fluoroamphetamine (C9H12FN), also known as para-fluoroamphetamine (PFA) 4-MA 4-Methylamphetamine (C10H15N) ADHD Attention Deficit Hyperactivity Disorder ATS Amphetamine Type Stimulants ATTUNE study Understanding Pathways to Stimulant Use: a mixed-methods ex- amination of the individual, social and cultural factors shaping illicit stimulant use across Europe CDU Currently Dependent User CNU Non-dependent Current frequent User EMCDDA The European Monitoring Centre for Drugs and Drug Addiction EU European Union FDU Formerly Dependent User FFU
    [Show full text]
  • 4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3
    4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 4.3 4-FA Contents Acknowledgements.................................................................................................................................. 4 Summary...................................................................................................................................................... 5 1. Substance identification ....................................................................................................................... 6 A. International Nonproprietary Name (INN).......................................................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 6 C. Other Chemical Names ................................................................................................................................................... 6 D. Trade Names ....................................................................................................................................................................... 6 E. Street Names ....................................................................................................................................................................... 6 F. Physical Appearance ......................................................................................................................................................
    [Show full text]
  • Long-Term Stability of Synthetic Cathinones in Forensic Toxicology Samples Author(S): Sarah Kerrigan, Ph.D., Lindsay Glicksberg, B.S
    NCJRS OFFICE OF JUSTICE PROGRAMS ~ N ATIONAL CRIMINAL JUSTICE REFERENCE SERVICE QJA BJS N/J OJJ[l> OVC SMART ",iiiii~ The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Long-Term Stability of Synthetic Cathinones in Forensic Toxicology Samples Author(s): Sarah Kerrigan, Ph.D., Lindsay Glicksberg, B.S. Document Number: 251194 Date Received: October 2017 Award Number: 2013-R2-CX-K006 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Contents Abstract........................................................................................................................................... 4 Executive Summary ........................................................................................................................ 6 I. Introduction .......................................................................................................................... 10 Statement of the Problem ........................................................................................................ 10 Literature Citations and Review ................................................................................................ 11 Use and
    [Show full text]
  • 4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 5.4
    4-Fluoroamphetamine (4-FA) Critical Review Report Agenda item 5.4 Expert Committee on Drug Dependence Thirty-seventh Meeting Geneva, 16-20 November 2015 37th ECDD (2015) Agenda item 5.4 4-Fluoroamphetamine Page 2 of 35 37th ECDD (2015) Agenda item 5.4 4-Fluoroamphetamine Page 3 of 35 37th ECDD (2015) Agenda item 5.4 4-Fluoroamphetamine Contents Acknowledgements .......................................................................................................................... 6 Summary .......................................................................................................................................... 7 1. Substance identification ................................................................................................................ 8 A. International Nonproprietary Name (INN) .................................................................................... 8 B. Chemical Abstract Service (CAS) Registry Number ...................................................................... 8 C. Other Names .................................................................................................................................. 8 D. Trade Names .................................................................................................................................. 8 E. Street Names .................................................................................................................................. 8 F. Physical properties .......................................................................................................................
    [Show full text]
  • Mephedrone, Methedrone, and Methylone Meph, M-Cat, MCAT, Miaow, Miaew, 4-Mmc, Bubbles, White Magic, Plant Feeder
    Essential Drugs & Alcohol Services Mephedrone, Methedrone, and Methylone Meph, m-cat, MCAT, Miaow, miaew, 4-mmc, bubbles, white magic, plant feeder What is it? Mephedrone (4-methylmethcathinone) is a stimulant which is closely chemically related to amphetamines. Users report that mephedrone produces a similar experience to drugs like amphetamines, ecstasy or cocaine. Mephedrone is a white, off-white or yellowish powder which is usually snorted, but can also be swallowed in bombs (wraps of paper) and may also appear in pill or capsule form. Mephedrone is probably the most well known of a group of drugs derived from cathinone (the same chemical found in the plant called khat) although two other compounds are also increasingly recognised on the market. These are methedrone and methylone. The effects of methedrone are said to be broadly similar to mephedrone, although methylone is said to give the user an experience more closely related to taking ecstasy (1). Other less common compounds from the cathinone family that may be used recreationally include flephedrone (4-FMC), bromomethcathinone ( 4-BMC), ethylone (MDEC), MDPV (methylenedioxypyrovalerone) and buphedrone and it is possible that other compounds are in circulation. Prevalence It is not known how many people use mephedrone, methedrone, methylone or related cathinone derivatives in the UK. As yet, these drugs do not feature in any of the major surveys of drug use such as the British Crime Survey Drug Misuse Declared bulletin. However, anecdotal evidence suggests that the drugs have become popular among club-goers and among more general recreational drug users. Prior to their classification under the Misuse of Drugs Act, they could be bought legally on the internet or in headshops.
    [Show full text]
  • And Synthetic Cathinones in Urine Using Solid Phase Micro-Extraction
    Analytical Methods View Article Online PAPER View Journal | View Issue Determination of amphetamine-type stimulants (ATSs) and synthetic cathinones in urine using solid Cite this: Anal. Methods,2018,10,1431 phase micro-extraction fibre tips and gas chromatography-mass spectrometry Khalid A. Alsenedi *a and Calum Morrison *b In recent years, an increasing number of stimulant drugs and new psychoactive substances (NPSs) have caused concern in scientific communities and therefore innovative methods to extract compounds from complex biological samples are required. This work is aimed at developing and validating a clean, convenient and straightforward extraction procedure with microliter amounts of organic solvent using Solid Phase Micro-Extraction tips (SPME tips) and analysis using Gas Chromatography-Mass Spectrometry (GC-MS) in human urine samples. Another aim is to evaluate three different types of SPME fibre tips C18, C18-SCX (mixed mode) and PDMS-DVB. The quantification method examined the Creative Commons Attribution 3.0 Unported Licence. different classes of stimulant compounds included Amphetamine-Type Stimulants (ATSs) (amphetamine, methamphetamine, para-methoxyamphetamine (PMA), and (Æ)-3,4-methylenedioxymethamphetamine (MDMA)) and synthetic cathinones (mephedrone, buphedrine (buphedrone ephedrine metabolite), 4- methylephedrine (mephedrone metabolite), and pentylone). The method was developed with respect to several areas of the experimental design including pH, ionic strength, addition of salts, vial dimensions, analytes and derivatisation, type of solvents, solvent volume, extraction and desorption time, agitation speeds in the extraction and desorption steps and matrix volume. The optimised method was validated for eight compounds using the SPME PDMS/DVB fibre tips with satisfactory linearity and selectivity À1 This article is licensed under a ranging between 50 and 2000 ng mL , and limits of detection (LODs) and low limits of quantification (LLOQs) ranging between (5–25) and (25–100) ng mLÀ1 respectively.
    [Show full text]
  • Synthetic Cathinones (Bath Salts): an Emerging Domestic Threat Cox Broadcasting
    U.S. Department of Justice National Drug Intelligence Center July 2011 Situation Report Product Number 2011-S0787-004 Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat Cox Broadcasting. Cox Broadcasting. Executive Summary The National Drug Intelligence Center (NDIC) assesses with high confidence that the distribu- tion and abuse of synthetic cathinones will increase in the United States in the near term, pos- ing yet another challenge to U.S. law enforcement officials. Poison control centers and medical professionals around the country are increasingly reporting patients suffering adverse physical effects associated with abuse of these drugs, further compounding the problem. Available data and law enforcement reporting suggest increasing levels of synthetic cathinone availability and abuse, but such information is limited and precise levels are unknown. U.S. Cus- toms and Border Protection (CBP) currently tracks seizures of synthetic cathinones at U.S. ports of entry (POEs), but many synthetic cathinone products are disguised or mislabeled to impede detection. Because common field test kits, drug-detecting canines, and routine urine drug screens do not detect synthetic cathinones, law enforcement officials are challenged in interdicting such drugs and prosecuting their manufacturers and distributors. Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat Synthetic cathinones, typically marketed as “bath salts” and “plant food,” are sold legally un- der various names (Ivory Wave, Blizzard, etc.) in most areas of the United States. The products are generally sold in retail establishments such as adult stores, independently owned convenience stores, gas stations, head shops, and skateboard shops. The products, as well as their raw chemi- cal components, are also sold on many Internet sites, including popular Internet auction sites.
    [Show full text]
  • Mephedrone – an Update on Current Knowledge
    Mephedrone – an update on current knowledge [Briefing prepared December 2009] Briefing prepared by Dr Harry Sumnall and Olivia Wooding, Centre for Public Health, Liverpool John Moores University, Kingsway House, Hatton Garden, Liverpool L3 2AJ. Contact: [email protected] Web: www.cph.org.uk 1 This briefing presents information on the substance Mephedrone (also known as: 4‐ MMC, ‘Meow’, ‘M‐Cat’) and other related drugs. This substance has received recent media attention concerning its legality and (largely unconfirmed) speculations around its contribution to the deaths of several young people. Little scientific evidence is available on mephedrone and most information is derived from users themselves or user orientated websites such as www.erowid.org . FRANK has some general information on mephedrone (www.talktofrank.com ). Key points • Mephedrone and related drugs are currently legal and have no licensed medicinal use. The ACMD is currently reviewing evidence and is expected to advise Government in 2010. • Mephedrone is usually available as tablets or powder. • It costs around £3 for a dose and produces effects that users report are similar, but not identical to, ecstasy/MDMA. Bulk purchases up to 1kg are significantly discounted by retailers. • The effects last for around 2 to 3 hours when taken orally. After effects such as insomnia may last for several hours longer. • Negative effects appear to be dose related and are similar to ecstasy/MDMA. They include: a desire to redose, uncomfortable changes in body temperature (sweating and chills), heart palpitations, impaired short term memory, insomnia, tightened jaw muscles, grinding teeth (trismus and bruxia), and light headedness.
    [Show full text]